Stockscreener 앱 받기
10.27
0.79%
0.08
시간 외 거래:
10.13
-0.14
-1.36%
전일 마감가:
$10.19
열려 있는:
$10.18
하루 거래량:
18,550
Relative Volume:
0.02
시가총액:
$11.48M
수익:
-
순이익/손실:
$-13.52M
주가수익비율:
-13.88
EPS:
-0.74
순현금흐름:
$-10.03M
1주 성능:
-0.87%
1개월 성능:
+10.08%
6개월 성능:
+45.16%
1년 성능:
-68.81%
1일 변동 폭
$9.7247
$10.42
1주일 범위
$9.59
$12.00
52주 변동 폭
$2.86
$39.05
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
명칭
Kazia Therapeutics Limited Adr
전화
01161298780088
주소
140 WICKS RD, NEW SOUTH WALES 2113, NSW
KZIA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
10.27 | 14.09M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | Maxim Group | Buy |
| 2021-10-14 | 개시 | Maxim Group | Buy |
| 2021-01-05 | 개시 | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr 주식(KZIA)의 최신 뉴스
Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight - Barchart.com
Analysts Issue Forecasts for Novogen FY2025 Earnings - Defense World
Novogen (NASDAQ:KZIA) Upgraded by HC Wainwright to Strong-Buy Rating - Defense World
Novogen (NASDAQ:KZIA) Rating Increased to Strong-Buy at HC Wainwright - Defense World
Cancer Innovation Accelerates as Funding Cuts Loom and Biotechs Step Up - The Globe and Mail
Novogen (NASDAQ:KZIA) Shares Up 39.7% – Should You Buy? - Defense World
Ryde Group files US$100 M shelf; micro-cap float limits near-term raise | KZIA SEC FilingForm 424B3 - Stock Titan
Cancer Innovation Accelerates As Funding Cuts Loom And Biotechs Step Up - Barchart.com
Kazia Therapeutics stock soars after positive early cancer treatment data By Investing.com - Investing.com Nigeria
Kazia Therapeutics stock soars after positive early cancer treatment data - Investing.com
Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial - Yahoo Finance
Short Interest in Novogen Limited (NASDAQ:KZIA) Declines By 28.0% - Defense World
Biotech Stocks To Add to Your Watchlist – June 11th - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Receives Buy Rating from Maxim Group - Defense World
United States shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.00% - Investing.com UK
Kazia’s paxalisib shows promise in breast cancer preclinical study - Investing.com
Kazia’s paxalisib shows promise in breast cancer preclinical study By Investing.com - Investing.com India
Breakthrough: New Drug Paxalisib Successfully Combats Triple-Negative Breast Cancer Resistance in Preclinical Study - Stock Titan
Kazia's Brain Cancer Drug Now Targets Breast Cancer: First Patient Starts Groundbreaking Combination Trial - Stock Titan
Kazia Therapeutics (NASDAQ:KZIA) Stock Price Up 26.7% – What’s Next? - Defense World
KAZIA'S PAXALISIB RECEIVES FAST TRACK DESIGNATION FROM FDA FOR TREATMENT OF SOLID TUMOR BRAIN METASTASES HARBORING PI3K PATHWAY MUTATIONS IN COMBINATION WITH RADIATION THERAPY - Barchart.com
Breast Cancer Treatment Market to reach $72B by 2033 with 9.4% CAGR growth | DataM IntelligenceNORTHEAST - NORTHEAST - NEWS CHANNEL NEBRASKA
Analysts Are Bullish on These Healthcare Stocks: Verastem (VSTM), Kazia Therapeutics (KZIA) - The Globe and Mail
Glioblastoma Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, NICE Approvals, Therapies and Companies by DelveInsight - The Globe and Mail
Kazia Therapeutics Highlights Recent Progress and Provides Business Update – Company Announcement - Financial Times
Kazia Therapeutics Highlights Recent Progress and Provides Business Update - Yahoo Finance
KAZIA THERAPEUTICS TO PRESENT AT BIO CEO CONFERENCE - marketscreener.com
Barclays PLC Invests $212,000 in Kazia Therapeutics Limited (NASDAQ:KZIA) - Defense World
Kazia Therapeutics (NASDAQ:KZIA) Shares Up 14.1% – Should You Buy? - Defense World
KAZIA THERAPEUTICS TO PRESENT AT HC WAINWRIGHT BIOCONNECT CONFERENCE - marketscreener.com
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com
United States shares mixed at close of trade; Dow Jones Industrial Average down 1.33% - Investing.com India
Kazia announces voluntary delisting from ASX - marketscreener.com
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com
GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 1.33% - Investing.com
Kazia Therapeutics-Plans To Change Ratio Of Its Adss To Ordinary Shares To One ADS Representing 500 Ordinary Shares - marketscreener.com
Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India
Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan
Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa
Kazia Therapeutics shares annual report details - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace
Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com
Kazia Therapeutics Limited Adr (KZIA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.64%
0.37%
자본화:
|
볼륨(24시간):